|
Feb 24
|
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
|
|
Feb 21
|
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
|
|
Feb 18
|
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
|
|
Feb 7
|
Pagaya Technologies And 2 Other High Growth Tech Stocks In The US
|
|
Dec 16
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Sep 27
|
High Growth Tech Stocks in the United States to Watch
|
|
Aug 26
|
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Jun 26
|
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
|
|
Jun 11
|
Alvotech and STADA add to strategic alliance through denosumab partnership
|
|
Jun 7
|
Alvotech Announces Strategic Refinancing Agreement
|
|
May 2
|
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
|
|
Jan 29
|
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
|
|
Jan 19
|
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
|
|
Jan 10
|
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
|
|
Nov 29
|
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
|
|
Nov 28
|
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
|
|
Nov 14
|
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
|
|
Nov 10
|
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
|
|
Nov 7
|
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
|
|
Aug 30
|
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
|